DelveInsight’s, “Angina pectoris - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Angina pectoris pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
• Global coverage
Angina pectoris Understanding
Angina pectoris: Overview
Angina pectoris is the medical term for chest pain or discomfort due to coronary heart disease. It occurs when the heart muscle doesn’t get as much blood as it needs. This usually happens because one or more of the heart’s arteries is narrowed or blocked, also called ischemia. Chest pain is the symptom, but it affects people differently. People may also experience: Aching, Burning, Discomfort, Dizziness, Fatigue, Feeling of fullness in your chest, Feeling of heaviness or pressure, Upset stomach or vomiting, Shortness of breath, Squeezing, Sweating. There are different types of angina:
Stable angina: This is the most common. Physical activity or stress can trigger it. It usually lasts a few minutes, and it goes away on rest.
Unstable angina: This occurs at rest or not very active. The pain can be strong and long-lasting, and it may come back again and again.
Microvascular angina: Chest pain but no coronary artery blockage.
Prinzmetal’s angina (variant angina): This type is rare. It might happen at night while sleeping or resting.
People with angina pectoris or sometimes referred to as stable angina have episodes of chest pain. The discomfort that are usually predictable and manageable. Normally this type of chest discomfort is relieved with rest, nitroglycerin or both. Nitroglycerin relaxes the coronary arteries and other blood vessels, reducing the amount of blood that returns to the heart and easing the heart’s workload. By relaxing the coronary arteries, it increases the heart’s blood supply.
• The companies and academics are working to assess challenges and seek opportunities that could influence Angina pectoris R&D. The therapies under development are focused on novel approaches for Angina pectoris.
Angina pectoris Emerging Drugs Chapters
This segment of the Angina pectoris report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Angina pectoris Emerging Drugs
• CLBS14: Caladrius Biosciences
CLBS14 is a Regenerative Medicine Advanced Therapy (“RMAT”) designated therapy for which the Company has finalized with the U.S. Food and Drug Administration a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina (“NORDA”). It is being developed by Caladrius Biosciences.
• IMB-101: Imbria pharmaceticals
IMB-101 is a novel, investigational cardiac mitotrope in development for the treatment of cardiovascular disease. As a partial fatty acid oxidation (pFOX) inhibitor, IMB-101 is designed to shift myocardial substrate utilization in favor of glucose oxidation to generate more ATP per unit of oxygen consumed thereby increasing myocardial metabolic efficiency.
It is currently in Phase II stage of development for Angina pectoris and is being developed by Imbria pharmaceticals.
Further product details are provided in the report??..
Angina pectoris: Therapeutic Assessment
This segment of the report provides insights about the different Angina pectoris drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players working on Angina pectoris
There are approx. 5+ key companies which are developing the Angina pectoris. The companies which have their Angina pectoris drug candidates in the most advanced stage, i.e. Phase III include, Caladrius Biosciences.
DelveInsight’s report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Angina pectoris pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Small molecule
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Angina pectoris: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Angina pectoris therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Angina pectoris drugs.
Angina pectoris Report Insights
• Angina pectoris Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs
Angina pectoris Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs
Current Scenario and Emerging Therapies:
• How many companies are developing Angina pectoris drugs?
• How many Angina pectoris drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Angina pectoris?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Angina pectoris therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Angina pectoris and their status?
• What are the key designations that have been granted to the emerging drugs?
• Imbria pharmaceticals
• Arbor Pharmaceuticals
• Caladrius Biosciences
• XyloCor Therapeutics
• CLBS 14